Lexicon Pharmaceuticals, Inc. (LXRX)
NASDAQ: LXRX · Real-Time Price · USD
0.715
-0.009 (-1.23%)
At close: Dec 20, 2024, 4:00 PM
0.642
-0.073 (-10.17%)
After-hours: Dec 20, 2024, 7:55 PM EST
Lexicon Pharmaceuticals Revenue
Lexicon Pharmaceuticals had revenue of $1.75M in the quarter ending September 30, 2024, with 980.25% growth. This brings the company's revenue in the last twelve months to $5.23M, up 886.60% year-over-year. In the year 2023, Lexicon Pharmaceuticals had annual revenue of $1.20M with 766.19% growth.
Revenue (ttm)
$5.23M
Revenue Growth
+886.60%
P/S Ratio
39.76
Revenue / Employee
$18,347
Employees
285
Market Cap
258.36M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 1.20M | 1.07M | 766.19% |
| Dec 31, 2022 | 139.00K | -159.00K | -53.36% |
| Dec 31, 2021 | 298.00K | -23.70M | -98.76% |
| Dec 31, 2020 | 24.00M | -298.08M | -92.55% |
| Dec 31, 2019 | 322.07M | 258.86M | 409.54% |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
| Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Accolade | 441.03M |
| OraSure Technologies | 224.26M |
| Amylyx Pharmaceuticals | 196.49M |
| Zynex | 193.67M |
| Vanda Pharmaceuticals | 190.86M |
| AC Immune | 48.51M |
| Senseonics Holdings | 22.21M |
| aTyr Pharma | 235.00K |
LXRX News
- 1 day ago - US FDA declines to approve Lexicon Pharma's add-on diabetes drug - Reuters
- 1 day ago - Lexicon Announces Receipt of Complete Response Letter for Zynquista™ (sotagliflozin) - GlobeNewsWire
- 25 days ago - Lexicon Announces Completion of Enrollment in Phase 2B PROGRESS Study of LX9211 in Diabetic Peripheral Neuropathic Pain (DPNP) - GlobeNewsWire
- 26 days ago - Lexicon Pharmaceuticals to Participate in December Investor Conferences - GlobeNewsWire
- 4 weeks ago - Lexicon Pharmaceuticals to cut workforce by 60% to focus on drug development - Reuters
- 4 weeks ago - Lexicon to Reposition as Clinical Development-Focused Company Following Regulatory Update From FDA - GlobeNewsWire
- 4 weeks ago - Lexicon Appoints Ivan H. Cheung to Board of Directors - GlobeNewsWire
- 5 weeks ago - Lexicon Pharmaceuticals, Inc. (LXRX) Q3 2024 Earnings Call Transcript - Seeking Alpha